Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents

J Neural Transm Park Dis Dement Sect. 1990;2(2):79-89. doi: 10.1007/BF02260896.

Abstract

Catalepsy was observed in the rat following intrastriatal injections of the dopamine antagonists sulpiride or fluphenazine and after subcutaneous administration of fluphenazine. The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole. The D1 agonist SKF 38393, and the D1/D2 agonist apomorphine, were ineffective in this model. These results support limited use of the rat catalepsy model for the screening of potential anti-parkinsonian compounds and indicate that this procedure can provide valuable information concerning striatal dopamine function.

MeSH terms

  • Animals
  • Antipsychotic Agents / pharmacology*
  • Catalepsy / chemically induced*
  • Catalepsy / physiopathology
  • Disease Models, Animal
  • Dopamine / physiology*
  • Dose-Response Relationship, Drug
  • Fluphenazine / pharmacology*
  • Levodopa / therapeutic use
  • Male
  • Methamphetamine / therapeutic use
  • Microinjections
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology*
  • Rats
  • Sulpiride / pharmacology*

Substances

  • Antipsychotic Agents
  • Methamphetamine
  • Levodopa
  • Sulpiride
  • Fluphenazine
  • Dopamine